CA2640835C - Immunoassay for the simultaneous immunochemical determination of an analyte (antigen) and a treatment antibody targeting the analyte in samples (recovery immunoassay) - Google Patents
Immunoassay for the simultaneous immunochemical determination of an analyte (antigen) and a treatment antibody targeting the analyte in samples (recovery immunoassay) Download PDFInfo
- Publication number
- CA2640835C CA2640835C CA2640835A CA2640835A CA2640835C CA 2640835 C CA2640835 C CA 2640835C CA 2640835 A CA2640835 A CA 2640835A CA 2640835 A CA2640835 A CA 2640835A CA 2640835 C CA2640835 C CA 2640835C
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- antibody
- ige
- immunoassay
- recovery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 55
- 102000036639 antigens Human genes 0.000 title claims abstract description 55
- 108091007433 antigens Proteins 0.000 title claims abstract description 55
- 238000011084 recovery Methods 0.000 title claims abstract description 55
- 238000003018 immunoassay Methods 0.000 title claims abstract description 38
- 239000012491 analyte Substances 0.000 title claims abstract description 12
- 230000000984 immunochemical effect Effects 0.000 title claims abstract description 10
- 230000008685 targeting Effects 0.000 title claims abstract description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 14
- 230000001419 dependent effect Effects 0.000 claims description 8
- 238000012421 spiking Methods 0.000 claims description 6
- 238000000611 regression analysis Methods 0.000 claims description 2
- 230000027455 binding Effects 0.000 abstract description 2
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 210000002966 serum Anatomy 0.000 description 33
- 238000003556 assay Methods 0.000 description 32
- 238000007792 addition Methods 0.000 description 28
- 230000004044 response Effects 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 229960000470 omalizumab Drugs 0.000 description 11
- 229940099073 xolair Drugs 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- 238000013461 design Methods 0.000 description 10
- 238000002965 ELISA Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000012886 linear function Methods 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000006911 enzymatic reaction Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000007620 mathematical function Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102100040247 Tumor necrosis factor Human genes 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012417 linear regression Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960002806 daclizumab Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001912 oat gum Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 235000011149 sulphuric acid Nutrition 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 238000002872 Statistical quality control Methods 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229960003115 certolizumab pegol Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 229940048921 humira Drugs 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002761 liquid phase assay Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 229940116176 remicade Drugs 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229940115586 simulect Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102005057920.5 | 2005-12-02 | ||
| DE102005057920A DE102005057920A1 (de) | 2005-12-02 | 2005-12-02 | Immunoassay zur simultanen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers in Proben |
| PCT/DE2006/002107 WO2007062628A2 (de) | 2005-12-02 | 2006-11-29 | Immunoassay zur simultanen immunchemischen bestimmung eines analyten (antigen) und eines gegen den analyten gerichteten therapieantikörpers in proben (recovery immunoassay) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2640835A1 CA2640835A1 (en) | 2007-06-07 |
| CA2640835C true CA2640835C (en) | 2014-03-18 |
Family
ID=37965064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2640835A Expired - Fee Related CA2640835C (en) | 2005-12-02 | 2006-11-29 | Immunoassay for the simultaneous immunochemical determination of an analyte (antigen) and a treatment antibody targeting the analyte in samples (recovery immunoassay) |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20080280311A1 (enExample) |
| EP (1) | EP1957980B1 (enExample) |
| JP (1) | JP4918556B2 (enExample) |
| AT (1) | ATE454629T1 (enExample) |
| CA (1) | CA2640835C (enExample) |
| DE (2) | DE102005057920A1 (enExample) |
| WO (1) | WO2007062628A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102009034714A1 (de) * | 2009-07-24 | 2011-01-27 | Biotez Berlin-Buch Gmbh Biochemisch-Technologisches Zentrum | Immunoassay zur Bestimmung des freien Targets (Antigen) in Proben, gegen das ein therapeutischer Antikörper gerichtet ist (Free Target Immunoassay) |
| AU2010315547C1 (en) | 2009-10-26 | 2015-06-04 | Société des Produits Nestlé S.A. | Assays for the detection of anti-TNF drugs and autoantibodies |
| AU2011317149B2 (en) | 2010-10-18 | 2015-05-07 | Société des Produits Nestlé S.A. | Methods for determining anti-drug antibody isotypes |
| DE102010050140A1 (de) | 2010-11-03 | 2012-05-03 | Biotez Berlin-Buch Gmbh | Recovery Immunoassay zur gleichzeitigen immunchemischen Bestimmung eines Analyten (Antigen) und eines gegen den Analyten gerichteten Therapieantikörpers |
| RU2013158256A (ru) | 2011-07-06 | 2015-07-10 | Нестек С.А. | АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα |
| US20130266963A1 (en) * | 2011-07-06 | 2013-10-10 | Nestec S.A. | Assay for detecting neutralizing autoantibodies to biologic therapy |
| ES2735085T3 (es) | 2014-12-05 | 2019-12-16 | Nestle Sa | Ensayos de cambio de movilidad homogéneos indirectos para la detección de agentes biológicos en muestras de pacientes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4138712A1 (de) * | 1991-11-20 | 1993-05-27 | Pavel Dr Strohner | Verfahren zur schnelloptimierung und gezielten qualitaetskontrolle von immunoassays aller provenienzen sowie vorrichtung zur durchfuehrung des verfahrens |
| JPH0772150A (ja) * | 1993-09-02 | 1995-03-17 | Tonen Corp | ＩｇＥの測定方法 |
| DE19532655A1 (de) * | 1995-08-24 | 1997-02-27 | Pavel Dr Strohner | Verfahren zur zweidimensionalen Bestimmung von Proben in Immunoassays |
| US5945294A (en) * | 1996-11-26 | 1999-08-31 | Heska Corporation | Method to detect IgE |
| US6127130A (en) * | 1998-03-13 | 2000-10-03 | The United States Of America As Represented By The Secretary Of The Navy | Multiassay method for determining the concentrations of antigens and interferants |
| JP2002350447A (ja) * | 2001-05-24 | 2002-12-04 | Wako Pure Chem Ind Ltd | 生理活性物質固定化担体及びその製造方法、固定化生理活性物質、試料中の対象成分分析方法、並びに試料中の対象成分分析用キット |
| GB0509512D0 (en) * | 2005-05-10 | 2005-06-15 | Novartis Ag | Organic compounds |
-
2005
- 2005-12-02 DE DE102005057920A patent/DE102005057920A1/de not_active Withdrawn
-
2006
- 2006-11-29 WO PCT/DE2006/002107 patent/WO2007062628A2/de not_active Ceased
- 2006-11-29 JP JP2008542594A patent/JP4918556B2/ja not_active Expired - Fee Related
- 2006-11-29 DE DE502006005889T patent/DE502006005889D1/de active Active
- 2006-11-29 US US12/095,776 patent/US20080280311A1/en not_active Abandoned
- 2006-11-29 AT AT06828568T patent/ATE454629T1/de active
- 2006-11-29 CA CA2640835A patent/CA2640835C/en not_active Expired - Fee Related
- 2006-11-29 EP EP06828568A patent/EP1957980B1/de not_active Not-in-force
Also Published As
| Publication number | Publication date |
|---|---|
| ATE454629T1 (de) | 2010-01-15 |
| WO2007062628A3 (de) | 2007-07-19 |
| JP4918556B2 (ja) | 2012-04-18 |
| DE102005057920A1 (de) | 2007-06-28 |
| WO2007062628A2 (de) | 2007-06-07 |
| DE502006005889D1 (de) | 2010-02-25 |
| EP1957980B1 (de) | 2010-01-06 |
| EP1957980A2 (de) | 2008-08-20 |
| JP2009517667A (ja) | 2009-04-30 |
| US20080280311A1 (en) | 2008-11-13 |
| CA2640835A1 (en) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2322562B1 (en) | Monoclonal antibody, and immunoassay using same | |
| CN104470942B (zh) | 生物标志物 | |
| US20070166776A1 (en) | Immunoassay and kit for an early and simultaneous detection of biochemical markers in a patient's sample | |
| US20250043024A1 (en) | Novel anti-thymidine kinase antibodies | |
| US7244555B2 (en) | Systems and methods for identifying organ transplant risk | |
| Drijvers et al. | The enzyme-linked immunosorbent assay: the application of ELISA in clinical research | |
| EP3264085A1 (en) | Immunoassay method and assay reagent used in said method | |
| CA2640835C (en) | Immunoassay for the simultaneous immunochemical determination of an analyte (antigen) and a treatment antibody targeting the analyte in samples (recovery immunoassay) | |
| US12459997B2 (en) | Compounds and methods targeting interleukin-19 | |
| AU645981B2 (en) | Removal of human anti-murine and heterophilic antibody interference in double antibody EIA assays | |
| CN114573692A (zh) | 用于检测嗜铬粒蛋白a的免疫测定与抗体 | |
| RU2607588C2 (ru) | Способ получения агента, связывающегося с препро-вазопрессином или с его фрагментами | |
| EP4286850A1 (en) | Immunological assay method | |
| JP2009517667A5 (enExample) | ||
| CN106053825B (zh) | 标定试剂和方法 | |
| US20210199659A1 (en) | Thymidine kinase (tk-1) in prognostic indices for dlbcl | |
| US20060252097A1 (en) | Detection of carbohydrate biomarkers | |
| CA2771954A1 (en) | Pneumonia biomarkers | |
| CA2825954A1 (en) | Use of galectin-3 for detecting and prognosing heart failure after acute coronary syndrome | |
| US20060275849A1 (en) | Monoclonal antibody reagents | |
| JPH03135766A (ja) | ヒトｉｌ―６の免疫化学的測定法及びそのためのキット | |
| AU2002346529B2 (en) | Immunoassay and kit for an early and simulataneous detection of biochemical markers in a patient's sample | |
| US20120115168A1 (en) | Bioassay and peptides for use therein | |
| CA2059122A1 (en) | Removal of human anti-murine and heterophilic antibody interference in double antibody eia assays |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20211129 |